Core Viewpoint - The article discusses the upcoming SynBioCon 2025 conference, focusing on the research and industrial applications of poly-γ-glutamic acid (γ-PGA), a biopolymer with significant potential in various fields such as functional foods, cosmetics, biomedicine, and biomaterials [1][3]. Summary by Sections γ-PGA Characteristics and Applications - γ-PGA's physiological functions and application areas are highly dependent on the proportion of L-glutamic acid monomers and molecular weight, with low molecular weight γ-PGAs (Mw<500 kDa) suitable for drug delivery and tissue engineering, while high molecular weight γ-PGAs (Mw>1500 kDa) serve as thickeners or flocculants [2]. Industrial Biotechnology Challenges - The efficient biosynthesis of γ-PGA from scratch and the directed synthesis of γ-PGA with varying L-glutamic acid monomer ratios and molecular weights are critical industrial biotechnology challenges that need to be addressed [3]. SynBioCon 2025 Conference Details - The SynBioCon 2025 conference will be held from August 20-22 in Ningbo, Zhejiang, focusing on the intersection of AI and biological manufacturing, as well as advancements and opportunities in green chemicals, new materials, future foods, future agriculture, and cosmetic raw materials [7][8]. - The conference will feature a special session, the "Youth Forum on Biological Manufacturing," aimed at providing insights into scientific issues, solutions, results, scalability, and future directions in the research field [7][8]. Conference Agenda - The agenda includes registration, a closed-door seminar for industry leaders, project roadshows, and various forums covering topics such as green chemicals, new materials, and future foods and agriculture [8][10].

Core Viewpoint - The article highlights the upcoming "Youth Forum on Biomanufacturing" scheduled for August 20 in Ningbo, Zhejiang, as part of the SynBioCon 2025 event, aimed at promoting innovation and collaboration in the field of synthetic biology and biomanufacturing [2][3]. Group 1: Event Details - The "Youth Forum on Biomanufacturing" will focus on addressing scientific issues, solutions, achievements, scalability, and future directions in the research field [3]. - The event will take place on August 20, 2025, with limited seating available (only 30 seats) [6]. - Participants can choose to register for either the Youth Forum or the Technology Achievement Showcase [6]. Group 2: Participation and Contributions - The event encourages universities and research institutions to apply for sharing their innovative achievements [4]. - SynBioCon 2025 will also feature a "Technology Achievement Showcase" to publicly collect 100 innovative achievements and projects in the field of synthetic biology and biomanufacturing for on-site display and networking [6]. Group 3: Organizers and Previous Events - The event is organized by Ningbo Detaizhongyan Information Technology Co., Ltd. (DT New Materials) and co-organized by Ningbo Meisai Biological Engineering Co., Ltd. [11]. - Previous editions of the SynBioCon were successfully held in 2022, 2023, and 2024 in Ningbo, showcasing the growing interest and development in the field [13].

Core Viewpoint - The article emphasizes the growing interest in the development of new carbon sources and biotechnological conversion, particularly in the context of industrial carbon-rich gas fermentation for fuel ethanol production. Group 1: Industrial Carbon-Rich Gas Fermentation Technology - The anaerobic microorganisms utilize the Wood-Ljungdahl pathway to absorb and fix CO and CO2 from industrial carbon-rich gases, synthesizing products like acetic acid and ethanol. The main advantages of this technology include low energy consumption, high safety, strong substrate specificity of enzymes, and high adaptability to raw material gas composition [3][4]. - The overall efficient conversion process is identified as a core challenge for scaling up industrial applications, closely related to stable gas supply, efficient strain development, fermentation process optimization, and market prospects [3][4]. Group 2: Progress of Industrial Carbon-Rich Gas Biomanufacturing Enterprises - Companies like LanzaTech and Jupeng Bio have established multiple industrial fermentation facilities. LanzaTech, a leader in gas fermentation, has formed a joint venture with Shougang Group, operating four production bases in China with an annual capacity of 210,000 tons of fuel ethanol and 23,200 tons of microbial protein by 2025 [4][6]. - Jupeng Bio is noted for its unique full-chain technology from biomass gasification to gas fermentation, with a demonstration plant completed in 2021 and a large-scale commercial facility under construction in Inner Mongolia [6][8]. - Other companies such as Synata Bio and Jitai Laibo Bio are rapidly developing in this field, with Synata Bio's 10-ton gas fermentation facility already completed [7][8]. Group 3: Challenges in Industrialization - The technology faces four main challenges: 1. **Gas Source Stability**: Variability in gas composition and quantity from upstream industries can affect the growth and metabolism of acetic acid-producing bacteria, potentially leading to fermentation system failure [9]. 2. **Process Control Precision**: There is a need for precise control technologies for gas inflow and product composition, as current methods for monitoring CO levels are inadequate [10][11]. 3. **Reactor Design**: Existing reactors often have low capacity and high production costs, necessitating the development of larger reactors while considering efficiency and operational costs [16][17]. 4. **Separation and Purification**: The low concentration of ethanol in fermentation necessitates the development of new separation technologies to reduce energy consumption during purification [20][22]. Group 4: Upcoming Industry Events - The Fourth Synthetic Biology and Green Bio-Manufacturing Conference will be held from August 20-22, 2025, in Ningbo, Zhejiang, focusing on new carbon source exploration and bioconversion opportunities [23][28].

Core Viewpoint - The article highlights the approval of alulose by the National Health Commission, marking the first instance of a company using synthetic biology to produce this new food ingredient in China [1][2]. Group 1: Approval and Technology - The AS10 strain fermentation method for producing alulose is the first case in China to receive approval for a new food ingredient using synthetic biology technology [2]. - The unique "one-step fermentation" process developed by the company simplifies production and enhances product quality compared to traditional methods [2][3]. Group 2: Cost Reduction and Market Potential - Previously, alulose production required a two-step conversion with an efficiency of only about 10%, leading to high market prices around 30,000 yuan per ton [4]. - With the optimization of synthetic biology technology, production costs are expected to decrease by 50%, potentially lowering prices to around 10,000 yuan per ton, which would significantly expand its market applications [5]. Group 3: Production Capacity and Future Plans - The company's first-phase alulose factory in Qinhuangdao has commenced operations, and a second-phase factory is set to begin production in 2027 [7]. - The company is also collaborating with traditional bio-manufacturing partners to upgrade multiple production capacities, with a 60,000-ton capacity project in North China expected to be operational by October 2025, positioning the company as the largest alulose supplier globally [8].

Core Viewpoint - Meihua Biotech has successfully completed the acquisition of the amino acid business and assets from Concord Fermentation, enhancing its product and business structure in the synthetic biology sector [1]. Group 1: Acquisition Details - The acquisition was finalized on July 1, 2025, with a transaction price of approximately 16.8 billion Japanese yen, equivalent to about 833 million RMB [1]. - The final transaction price was adjusted based on the cash reserves and working capital of the target assets at the time of closing, which included an estimated cash amount of 11.3 billion Japanese yen (approximately 560 million RMB) [1]. - Concord Fermentation is recognized as a leader in biotechnology and fermentation, focusing on high-quality amino acids and other synthetic biology products [1]. Group 2: Business Expansion - The acquisition allows Meihua Biotech to diversify its product offerings by adding various new amino acid products and strains, enhancing its fermentation and refinement capabilities for high-value pharmaceutical amino acids [1]. - The company will also gain production capabilities and intellectual property for three types of Human Milk Oligosaccharides (HMO) through the integration of a precision fermentation platform [1]. - The acquisition supports the company's strategy to expand its industrial footprint internationally by acquiring multiple domestic and foreign operational entities [1]. Group 3: Financial Performance - In Q1 2025, the feed amino acid segment generated revenue of 2.939 billion RMB, accounting for approximately 46.9% of total revenue, marking a year-on-year increase of 6.68% [2]. - The growth in this segment is attributed to the rise in both volume and price of lysine, as well as increased sales of threonine, positioning it as a potential new growth driver for the company [2].

Core Viewpoint - The article discusses the challenges and advancements in the industrialization of natural macromolecular active substances, highlighting a novel bioreactor developed to enhance fermentation processes for these substances [1][2][4]. Group 1: Challenges in Industrialization - Natural macromolecular active substances, such as polyamino acids, functional proteins, and microbial polysaccharides, face extraction difficulties due to their high molecular weight and complex conformations [1]. - The fermentation process of these substances is characterized by high viscosity, high oxygen demand, and high energy consumption, which complicates production [2][4]. - The accumulation of products during fermentation leads to high-viscosity non-Newtonian fluid characteristics, creating barriers that inhibit oxygen and nutrient metabolism, thus limiting yield improvements [1]. Group 2: Innovations in Bioreactor Technology - A new microbubble bioreactor platform has been developed using laser sintering 3D printing technology and computational fluid dynamics principles, aimed at overcoming the challenges of high-viscosity fermentation processes [2][4]. - This bioreactor design allows for the transition from macro to micro bubbles (less than 100 μm), significantly increasing the contact surface area between microorganisms and oxygen, thereby enhancing oxygen transfer efficiency by 120%-135% [4]. - The energy efficiency of the fermentation process is improved by 1.6 to 2.9 times compared to traditional bioreactors [4]. Group 3: Performance Improvements in Fermentation - The new bioreactor technology has been validated in a 7 L fermentation tank for the production of γ-polyglutamic acid (γ-PGA), achieving over a 40% increase in yield [5]. - The technology has also demonstrated versatility, with fermentation yields for other macromolecules such as mussel adhesive protein, panibacterial polysaccharide, welan gum, β-glucan, and ε-polylysine increasing by 79%, 58%, 39%, 50%, and 43% respectively [5]. Group 4: Implications for the Industry - This innovative research provides a reference and technical support for the efficient biosynthesis and industrial application of macromolecular active substances, as well as insights for enhancing fermentation processes in other synthetic biology products [7]. - The advancements in biomanufacturing are expected to contribute to the ongoing development of the synthetic biology industry, particularly in the context of green manufacturing and sustainable practices [7].

Core Insights - The article discusses the launch of the "Synthetic Human Genome Project" (SynHG), led by Professor Jason Chin from the University of Oxford, with funding of £10 million from the Wellcome Trust, aiming to chemically synthesize a complete human genome [1][2] - The project is expected to develop foundational tools and methods that will support future research in synthetic biology, potentially leading to new discoveries about how cells utilize their genomes [2][3] Group 1: Project Overview - SynHG is the first of its kind globally, with a goal to construct a complete human genome through chemical synthesis [1] - The project aims to establish a technical framework within five years and to synthesize a complete human chromosome within 5-10 years, facing significant scientific challenges [2] Group 2: Scientific Implications - Professor Jason Chin emphasizes that the ability to synthesize large genomes could fundamentally change the understanding of genomic biology and expand the capabilities of biotechnology and medicine [3] - The project is not about creating life but focuses on understanding gene expression regulation mechanisms [3] Group 3: Future Directions and Events - The upcoming "Synthetic Biology and Green Bio-Manufacturing Conference" (SynBioCon 2025) will take place from August 20-22 in Ningbo, Zhejiang, focusing on the intersection of AI and bio-manufacturing [4][5] - The conference will explore trends in bio-manufacturing, innovative technologies, and the potential for technology transfer and talent acquisition in the industry [4]

SynBioCon 大会 | 致力于科技成果转化 第四届合成生物与绿色生物制造大会 (简称：SynBioCon 2025) 将于 8月20-22日 在 浙江·宁波 举办，由DT新材料主办，酶赛生物协办，中国 生物工程学会生物基材料专业委员会、上海市未来产业生物制造专委会、广州合成生物产学研技术创新联盟共同支持 。 DT新材料致力于科技成果转移转化。SynBioCon大会聚焦产业生态发展与科技成果转移转化，已完成1000+次科研院所和初创项目对接。本届大会 同期将继续举办 特色活动 「合成生物制造创新科技成果展示与对接 」 ， 收集并 展示100个0~100的合成生物制造创新科技成果 ， 以 促进行 业高效科技成果与转化。 SynBioCon大会持续发布科技成果。本期介绍项目如下： 成果简介 L-哌啶甲酸，简称L-PA，是一种重要的刚性环状非蛋白质氨基酸，广泛用于罗哌卡因等手性药物和雷帕霉素等生物活性物质的制备。近来发现可作 为植物刺激素，激活植物免疫。 本技术利用先进代谢工程技术，通过从头设计合成路径和系统、优化大肠杆菌，构建了第一代生产哌啶甲酸的大肠杆菌细胞工厂，含IPTG诱导质粒， 遗传稳定，以赖氨酸无机 ...

SynBioCon 大会 | 同舟纵横 集"膜材料生产---工艺研发及装备制造---工艺设计---技术服务"为一体的物料分离全产业链企业—— 同舟纵横 将出席 2025年8月20-22日，浙江·宁波 举办的 SynBioCon 2025 第四届合成生物与绿色生物制造大会 同舟纵横 已入驻 全球生物基和生物制造产业服务 平台-新品库（ bio-basedlink ） 。 同舟纵横新品库网址 ： https://www.bio-basedlink.net/index/brand/brand_show/article_id/193.html ↓↓↓ 公司介绍 同舟纵横 (厦门)流体技术有限公司专注于工 业流体领域的分离纯化，是一家集材料生产 -工艺 研发 ---设备制造--药剂生产-EPC设计及工程总包为 一体的 国家级高新技术企业和国家级专精特新小巨 人企业。 多年来同舟纵横不断探索已经完成了数百工程 项目，涉及医药、化工、食品添加剂、淀粉糖、生 物发酵、植物提取、新能源、环保等各个领域， 在 实 战中公司积累了大量的工程经验，树立了良好的 行业口碑，已经成为了利用压力驱动膜技术板块、 电驱动膜技术板块和连续离交 ...

Core Viewpoint - The establishment of the AI4S synthetic biology intelligent research platform by Anhui Normal University, University of Science and Technology of China, and Wuhu Yijiang District aims to advance key technologies in synthetic biology, focusing on gene design, enzyme optimization, and biomanufacturing applications in various strategic emerging industries [1][6][10]. Group 1: Platform Overview - The AI4S platform will collaborate with over 20 enterprises and medical institutions, emphasizing breakthroughs in genome design and enzyme molecular modification [1][6]. - The platform integrates AI technology with automated experimental equipment to enhance experimental efficiency and data collection through high-throughput operations [3][8]. Group 2: Research Directions - The platform focuses on six major research areas: gene circuit design, enzyme discovery and optimization, metabolic pathway exploration, synthetic biology big data analysis, artificial cell factory creation, and biopharmaceutical synthesis [1][6]. - It aims to address critical challenges in biomanufacturing, including efficient gene design, experimental automation, data-driven optimization, and industrial-scale production [7][10]. Group 3: Technological Integration - The platform will create an integrated AI simulation and experimental validation system, combining high-performance computing and machine learning with experimental data [3][9]. - It will support virtual screening, experimental validation, and the establishment of cell factory models, enhancing the product development lifecycle [3][10]. Group 4: Industry Landscape - Multiple institutions in China have established similar synthetic biology platforms, including the Shenzhen Institute of Advanced Technology and Peking University, indicating a growing trend in the sector [4][6]. - Companies like BGI, Huaheng Biotechnology, and others are adopting AI and automated fermentation optimization platforms to accelerate product development [11]. Group 5: Future Prospects - With increasing policy support and industry demand, more institutions are expected to enter the field of synthetic biology and AI integration [12]. - The upcoming SynBioCon 2025 conference will focus on AI and biomanufacturing, exploring technological innovations and industry trends [14][16].